This is sponsored content issued on behalf of Voyageur Pharmaceuticals, please see full disclaimer here.
More From The Market Online
Unsung profits: Three microcap stocks with a strong case for value
A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.
- Trevor Abes
- 3 mins
- 24 April 2024 04:00 (EDT)
This life sciences company is gearing up to treat long COVID
Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.
- Jocelyn Aspa
- 3 mins
- 25 April 2024 06:00 (EDT)
Theralase advances cancer research after private placement
Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.
- Jonathon Brown
- 2 mins
- 24 April 2024 09:15 (EDT)
Takeover rumours: BioNTech, Cardiol Therapeutics and Novo Nordisk in focus
Biotech has lagged behind the performance of artificial intelligence and high-tech this year, but economic conditions might signal changes.
- André Will-Laudien
- 6 mins
- 24 April 2024 13:04 (EDT)